{"title":"非1类肺动脉高压住院患者中烟草使用障碍的患病率及其对院内死亡率的影响:2019年全国倾向得分匹配分析。","authors":"Rupak Desai, Zainab Gandhi, Saher Taj Shiza, Akhil Jain, Hiren Koshiya, Bibi Alli-Ramsaroop, Agatha Olawunmi Akinsete, Eko Wilson, Pranathi Rudra, Mohan Sai Sunith Vegesna, Madiha Bari, Ankit Vyas, Bisharah Rizvi, Salim Surani","doi":"10.17179/excli2023-6409","DOIUrl":null,"url":null,"abstract":"<p><p>Numerous studies indicated that patients with tobacco use disorder (TUD) are inversely associated with mortality in what is known as the smoker's paradox. However, limited studies have been conducted on the impact of TUD on the in-hospital mortality rates of patients with secondary pulmonary hypertension (PH, Non-Group 1 PH). Using the 2019 National Inpatient Sample, we identified PH and divided it into TUD and non-TUD to compare the comorbidities and in-hospital mortality between the two after 1:1 propensity-score matching. Of 1,129,440 PH hospitalizations, 12.1 % had TUD. After matching (n=133545, each group), TUD had lower median age (62 vs. 63), higher females (49 vs. 46.6 %), blacks (25.9 vs. 25.3 %), lower household income (40.8 vs. 32.7 %), Medicaid (22.4 vs. 14.8 %), non-elective (93.5 vs. 89.8 %), rural (9.3 vs. 6.7 %), urban non-teaching (17.2 vs 15.8 %) admissions. All CV comorbidities and other substance use were higher in TUD except CHF and valvular heart disease, TUD+ cohort and lower mortality (3.3 vs. 4.2 %, OR 0.78, p<0.001), higher routine discharges (53.8 vs. 51.3 %, p<0.001) and lower total charges ($47155 vs. 51909, p<0.001) than non-TUD. Although PH patients with TUD had a higher comorbidity burden, they had lower in-hospital mortality rates along with lower total charges of hospitalization, mandating real-world data to validate these results. See also the Graphical abstract(Fig. 1).</p>","PeriodicalId":12247,"journal":{"name":"EXCLI Journal","volume":"22 ","pages":"1200-1210"},"PeriodicalIF":3.8000,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10776876/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prevalence and impact of tobacco use disorder on in-hospital mortality in patients hospitalized with non-group 1 pulmonary hypertension: a nationwide propensity score-matched analysis, 2019.\",\"authors\":\"Rupak Desai, Zainab Gandhi, Saher Taj Shiza, Akhil Jain, Hiren Koshiya, Bibi Alli-Ramsaroop, Agatha Olawunmi Akinsete, Eko Wilson, Pranathi Rudra, Mohan Sai Sunith Vegesna, Madiha Bari, Ankit Vyas, Bisharah Rizvi, Salim Surani\",\"doi\":\"10.17179/excli2023-6409\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Numerous studies indicated that patients with tobacco use disorder (TUD) are inversely associated with mortality in what is known as the smoker's paradox. However, limited studies have been conducted on the impact of TUD on the in-hospital mortality rates of patients with secondary pulmonary hypertension (PH, Non-Group 1 PH). Using the 2019 National Inpatient Sample, we identified PH and divided it into TUD and non-TUD to compare the comorbidities and in-hospital mortality between the two after 1:1 propensity-score matching. Of 1,129,440 PH hospitalizations, 12.1 % had TUD. After matching (n=133545, each group), TUD had lower median age (62 vs. 63), higher females (49 vs. 46.6 %), blacks (25.9 vs. 25.3 %), lower household income (40.8 vs. 32.7 %), Medicaid (22.4 vs. 14.8 %), non-elective (93.5 vs. 89.8 %), rural (9.3 vs. 6.7 %), urban non-teaching (17.2 vs 15.8 %) admissions. All CV comorbidities and other substance use were higher in TUD except CHF and valvular heart disease, TUD+ cohort and lower mortality (3.3 vs. 4.2 %, OR 0.78, p<0.001), higher routine discharges (53.8 vs. 51.3 %, p<0.001) and lower total charges ($47155 vs. 51909, p<0.001) than non-TUD. Although PH patients with TUD had a higher comorbidity burden, they had lower in-hospital mortality rates along with lower total charges of hospitalization, mandating real-world data to validate these results. See also the Graphical abstract(Fig. 1).</p>\",\"PeriodicalId\":12247,\"journal\":{\"name\":\"EXCLI Journal\",\"volume\":\"22 \",\"pages\":\"1200-1210\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2023-11-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10776876/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EXCLI Journal\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.17179/excli2023-6409\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EXCLI Journal","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.17179/excli2023-6409","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
大量研究表明,烟草使用失调(TUD)患者的死亡率与吸烟者的悖论成反比。然而,关于 TUD 对继发性肺动脉高压(PH,非 1 组 PH)患者院内死亡率的影响的研究却很有限。我们利用2019年全国住院患者样本,对PH进行了识别,并将其分为TUD和非TUD,经过1:1倾向得分匹配后,比较了两者的合并症和院内死亡率。在 1,129,440 例 PH 住院病例中,12.1% 患有 TUD。经过匹配后(每组 n=133545 人),TUD 的中位年龄较低(62 岁 vs. 63 岁)、女性比例较高(49% vs. 46.6%)、黑人比例较高(25.9% vs. 25.3%)、家庭收入较低(40.8 vs. 32.7 %)、医疗补助(22.4 vs. 14.8 %)、非选择性(93.5 vs. 89.8 %)、农村(9.3 vs. 6.7 %)、城市非教学(17.2 vs. 15.8 %)入院。除慢性阻塞性肺病和瓣膜性心脏病外,所有慢性阻塞性肺病合并症和其他药物使用率在 TUD 中均较高。
Prevalence and impact of tobacco use disorder on in-hospital mortality in patients hospitalized with non-group 1 pulmonary hypertension: a nationwide propensity score-matched analysis, 2019.
Numerous studies indicated that patients with tobacco use disorder (TUD) are inversely associated with mortality in what is known as the smoker's paradox. However, limited studies have been conducted on the impact of TUD on the in-hospital mortality rates of patients with secondary pulmonary hypertension (PH, Non-Group 1 PH). Using the 2019 National Inpatient Sample, we identified PH and divided it into TUD and non-TUD to compare the comorbidities and in-hospital mortality between the two after 1:1 propensity-score matching. Of 1,129,440 PH hospitalizations, 12.1 % had TUD. After matching (n=133545, each group), TUD had lower median age (62 vs. 63), higher females (49 vs. 46.6 %), blacks (25.9 vs. 25.3 %), lower household income (40.8 vs. 32.7 %), Medicaid (22.4 vs. 14.8 %), non-elective (93.5 vs. 89.8 %), rural (9.3 vs. 6.7 %), urban non-teaching (17.2 vs 15.8 %) admissions. All CV comorbidities and other substance use were higher in TUD except CHF and valvular heart disease, TUD+ cohort and lower mortality (3.3 vs. 4.2 %, OR 0.78, p<0.001), higher routine discharges (53.8 vs. 51.3 %, p<0.001) and lower total charges ($47155 vs. 51909, p<0.001) than non-TUD. Although PH patients with TUD had a higher comorbidity burden, they had lower in-hospital mortality rates along with lower total charges of hospitalization, mandating real-world data to validate these results. See also the Graphical abstract(Fig. 1).
期刊介绍:
EXCLI Journal publishes original research reports, authoritative reviews and case reports of experimental and clinical sciences.
The journal is particularly keen to keep a broad view of science and technology, and therefore welcomes papers which bridge disciplines and may not suit the narrow specialism of other journals. Although the general emphasis is on biological sciences, studies from the following fields are explicitly encouraged (alphabetical order):
aging research, behavioral sciences, biochemistry, cell biology, chemistry including analytical chemistry, clinical and preclinical studies, drug development, environmental health, ergonomics, forensic medicine, genetics, hepatology and gastroenterology, immunology, neurosciences, occupational medicine, oncology and cancer research, pharmacology, proteomics, psychiatric research, psychology, systems biology, toxicology